Back To: Home



October 8 - November 10, 2014

November 2-5, 2014

More Events
Name:
Company:
Email:
 
 
 

Daiichi Sankyo, NGM partner up
May 2012
SHARING OPTIONS:

TOKYO—The end of March saw Daiichi Sankyo Co. Ltd. and NGM Biopharmaceuticals Inc. announcing a research collaboration and license agreement for the discovery and development of novel therapeutics that modulate beta-cell regeneration as a treatment for diabetes. Per the agreement, NGM will receive an upfront payment and committed research funding for the length of the partnership, and will use its integrate discovery technology and in-vivo screening platform to identify potential metabolic targets. NGM also stands to receive milestone payments based on the achievement of research, development, regulatory and commercial goals, as well as royalties on product sales. The agreement grants Daiichi Sankyo an exclusive worldwide license to develop and commercialize compounds that result from the collaboration. Daiichi Sankyo will be responsible for preclinical studies, clinical development, manufacturing and commercialization on a worldwide basis.

Back








CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2014 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.